🔓 Unlock the full profile of Kris Vaddi (Prelude Therapeutics), including verified contact details, financial insights, and professional associations.
See Kris Vaddi Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: kri*****@pre******.com
Mobile: 65166*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Kris Vaddi is the Chief Executive Officer and Founder of Prelude Therapeutics, based in Wilmington, Delaware, established in October 2016.
- Prelude Therapeutics focuses on developing targeted therapies for patients with cancer, emphasizing precision medicine.
- Under the leadership of Kris Vaddi, Prelude Therapeutics went public with its shares listed on NASDAQ under the symbol PRLD.
- The organization reported a market capitalization of approximately $46.2 million and has experienced growth in headcount over the past two years.
- Prior to founding Prelude Therapeutics, Kris Vaddi was involved with Orsenix as its Founder, starting in June 2014.
- Kris Vaddi's previous experience includes serving in senior roles at Incyte Corporation, where significant contributions were made as Group Vice President and Senior Advisor from 2010 to 2016.
- Before joining Incyte, Kris Vaddi worked at DuPont Pharmaceuticals and Genzyme Corporation, building a robust foundation in pharmaceuticals and biotechnology.
- The journey of Kris Vaddi in the biotech field reflects a commitment to innovation and patient-centric approaches to healthcare challenges.
- Prelude Therapeutics has built a reputation for its nimbleness and effectiveness in the highly competitive biopharmaceutical landscape.